Patents by Inventor Mao Bi

Mao Bi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of chimeric antigen receptor modified cells to treat cancer
    Patent number: 11932700
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: March 19, 2024
    Assignee: Innovative Cellular Therapeutics Holdings, Ltd.
    Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi, Zhao Wu
  • Modified Cell Expansion and Uses Thereof
    Publication number: 20220265708
    Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.
    Type: Application
    Filed: January 10, 2019
    Publication date: August 25, 2022
    Applicants: Innovative Cellular Therapeutics, Inc., Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu, Li Mao, Mao Bi
  • USE OF CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS TO TREAT CANCER
    Publication number: 20200385484
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 10, 2020
    Applicant: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi, Zhao Wu
  • Use of chimeric antigen receptor modified cells to treat cancer
    Patent number: 10793638
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: October 6, 2020
    Assignee: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi, Zhao Wu
  • Use of chimeric antigen receptor modified cells to treat cancer
    Patent number: 10654934
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: May 19, 2020
    Assignee: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi
  • USE OF CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS TO TREAT CANCER
    Publication number: 20180222995
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi, Zhao Wu
  • USE OF CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS TO TREAT CANCER
    Publication number: 20180179289
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Lei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi
  • Use of chimeric antigen receptor modified cells to treat cancer
    Patent number: 9932405
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 3, 2018
    Assignee: Innovative Cellular Therapeutics CO., LTD.
    Inventors: Lei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi
  • USE OF CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS TO TREAT CANCER
    Publication number: 20170355776
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Application
    Filed: August 24, 2017
    Publication date: December 14, 2017
    Inventors: Lei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi
  • METHOD FOR DIRECTIONAL CLONING
    Publication number: 20170218380
    Abstract: Described herein are techniques for directional cloning an insert DNA segments into a target vector. The techniques mix the target vector, the insert DNA segment, a restriction enzyme, and a DNA ligase to generate a recombinant DNA molecule.
    Type: Application
    Filed: April 7, 2017
    Publication date: August 3, 2017
    Inventors: Lei Xiao, Zhao Wu, Mao Bi